Skip to main content

 Scientific publications

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.

Authors : Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Bonotto M, Fernandez de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Sandri MT, Generali D, de Angelis C, Dawson SJ, Janni W, Carañana V, Riethdorf S, Solomayer EF, Puglisi F, Giuliano M, Pantel K, Bidard FC, Cristofanilli M
Year : 2022
Journal : Oncologist
Volume : 27
Pages : e561-e570

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Authors : Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, Macpherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart-Gebhart M, Regan MM
Year : 2022
Journal : Eur J Cancer
Volume : 164
Pages : 39-51

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.

Authors : Rothé F, Lambertini M, Goldrat O, Maetens M, Bareche Y, Blanc J, Rouas G, Larsimont D, Sotiriou C, Ignatiadis M, Demeestere I
Year : 2021
Journal : Front Oncol
Volume : 11
Pages : 686625

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Authors : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Year : 2021
Journal : BMC Cancer
Volume : 21
Pages : 899

Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.

Authors : Agostinetto E, Ignatiadis M
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 427-430

Liquid biopsy enters the clinic - implementation issues and future challenges.

Authors : Ignatiadis M, Sledge GW, Jeffrey SS
Year : 2021
Journal : Nat Rev Clin Oncol
Volume : 18
Pages : 297-312

Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.

Authors : Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 5482-5491

Cell-free circulating tumor DNA profiling in cancer management.

Authors : Roy D, Lucci A, Ignatiadis M, Jeffrey SS
Year : 2021
Journal : Trends Mol Med

Neoadjuvant immunotherapy in breast cancer: a paradigm shift?

Authors : Fountzila E, Ignatiadis M
Year : 2020
Journal : Ecancermedicalscience
Volume : 14
Pages : 1147

Clinical management of first-line advanced triple-negative breast cancer patients

Authors : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Year : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pages : 333-338

Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations.

Authors : Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr
Year : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 3012-3023

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.

Authors : Bohlok A, Vermeulen P, Leduc S, Latacz E, Botzenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart-Gebhart M, Hendlisz A, Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 64

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.

Authors : de Angelis C, Ignatiadis M, Piccart-Gebhart M
Year : 2020
Journal : Ann Transl Med
Volume : 8
Pages : 1338

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Authors : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Year : 2020
Journal : Eur J Cancer
Volume : 125
Pages : 69-82

Early prediction of neoadjuvant treatment outcome in locally advanced breast cancer using parametric response mapping and radial heterogeneity from breast MRI.

Authors : Drisis S, El Adoui M, Flamen P, Benjelloun M, de Wind R, Paesmans M, Ignatiadis M, Bali MA, Lemort M
Year : 2020
Journal : J Magn Reson Imaging
Volume : 51
Pages : 1403-1411

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Authors : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Authors : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77